Clinical trial

Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer

NCT01642771

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2012-06-01

PhasePHASE3

Study timeline

Study start (unknown)2012-06-01Date precision: month

Registry last updated2017-04-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

5-Fu/epirubicin/CTX following DocetaxelDRUG

Docetaxel/capecitabine followed by XECDRUG

Sponsors & collaborators

China Breast Cancer Clinical Study Grouplead sponsor

Mapped research locations

BeijingBeijing Municipality, China5 ShanghaiShanghai Municipality, China5 GuangzhouGuangdong, China2 HangzhouZhejiang, China2 ChangchunJilin, China2 ChongqingChongqing Municipality, China2 HarbinHeilongjiang, China2 ChangshaHunan, China1 WuhanHubei, China1 ZhengzhouHenan, China1 TianjinTianjin Municipality, China1 ShenyangLiaoning, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01642771 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.